Home pageKLBF • IDX
add
Kalbe Farma Tbk PT
Chiusura precedente
1190,00Â Rp
Intervallo giornaliero
1175,00Â Rp - 1195,00Â Rp
Intervallo annuale
985,00Â Rp - 1770,00Â Rp
Cap di mercato
55,71Â Bln IDR
Volume medio
72,87Â Mln
Rapporto P/E
15,96
Dividendo/Prezzo
3,03%
Borsa valori principale
IDX
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
(IDR) | giu 2025info | Variazione Y/Y |
---|---|---|
Entrate | 8,23Â Bln | 3,37% |
Spese di gestione | 2,24Â Bln | 10,65% |
Utile netto | 898,17Â Mld | 5,97% |
Margine di profitto netto | 10,91 | 2,54% |
Utili per azione | 19,78 | 8,50% |
EBITDA | 1,26Â Bln | 0,42% |
Aliquota fiscale effettiva | 23,09% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(IDR) | giu 2025info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 3,95Â Bln | 2,69% |
Totale attivo | 29,51Â Bln | 3,30% |
Totale passivo | 5,32Â Bln | 5,83% |
Patrimonio netto totale | 24,19 Bln | — |
Azioni in circolazione | 45,39 Mld | — |
Prezzo/valore contabile | 2,41 | — |
Redditività dell'attivo | 8,82% | — |
Rendimento sul capitale | 10,42% | — |
Flusso di cassa
Flusso di cassa netto
(IDR) | giu 2025info | Variazione Y/Y |
---|---|---|
Utile netto | 898,17Â Mld | 5,97% |
Liquidità di esercizio | 956,75 Mld | -17,88% |
Contanti da investimenti | 117,04Â Mld | 123,27% |
Contanti da finanziamenti | -1,78Â Bln | -47,25% |
Flusso di cassa netto | -740,01Â Mld | -90,86% |
Flusso di cassa libero | 667,76Â Mld | 18,23% |
Informazioni
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Fondazione
10 set 1966
Sito web
Dipendenti
12.832